Recent News

• 07.08.2026 - Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
• 06.30.2026 - Addex Shareholders Approve All Resolutions at Annual General Meeting
• 06.25.2026 - Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• 06.22.2026 - Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
• 02.03.2026 - Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
• 10.29.2025 - Addex Increases Issued Share Capital to Create Treasury Shares
• 09.30.2025 - Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
• 09.26.2025 - Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
• 09.23.2025 - Addex Appoints Bank of New York Mellon as Depositary Bank
• 06.30.2025 - Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Recent Filings

• 07.08.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.08.2026 - EX-99.1 EX-99.1
• 06.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.30.2026 - EX-99.1 EX-99.1
• 06.25.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.25.2026 - EX-99.1 EX-99.1
• 06.05.2026 - EX-99.1 EX-99.1
• 06.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.15.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 04.30.2026 - NT 20-F Notification of inability to timely file Form 20-F